Mark Massaro
Stock Analyst at BTIG
(3.62)
# 511
Out of 5,182 analysts
162
Total ratings
40.52%
Success rate
9.19%
Average return
Main Sectors:
Stocks Rated by Mark Massaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SOPH SOPHiA GENETICS | Maintains: Buy | $7 → $8 | $5.00 | +60.00% | 4 | Apr 15, 2026 | |
| LUCD Lucid Diagnostics | Reiterates: Buy | $2.5 | $1.04 | +140.38% | 5 | Mar 30, 2026 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Sell | $9 → $5 | $7.85 | -36.31% | 8 | Mar 12, 2026 | |
| XGN Exagen | Maintains: Buy | $10 → $9 | $2.73 | +229.67% | 7 | Mar 10, 2026 | |
| BLLN BillionToOne | Maintains: Buy | $160 → $140 | $78.23 | +78.96% | 3 | Mar 5, 2026 | |
| CAI Caris Life Sciences | Maintains: Buy | $45 → $38 | $18.44 | +106.07% | 1 | Feb 27, 2026 | |
| CDNA CareDx | Maintains: Buy | $25 → $26 | $21.91 | +18.67% | 6 | Feb 26, 2026 | |
| TEM Tempus AI | Maintains: Buy | $105 → $90 | $51.10 | +76.13% | 7 | Feb 25, 2026 | |
| WGS GeneDx Holdings | Maintains: Buy | $200 → $170 | $66.07 | +157.30% | 8 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $140 → $145 | $83.09 | +74.51% | 8 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $13 | $5.50 | +136.36% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $22 | $14.04 | +56.70% | 8 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $830 → $800 | $568.30 | +40.77% | 3 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.04 | +243.14% | 10 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $50 | $24.69 | +102.51% | 6 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $260 | $200.17 | +29.89% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $116.65 | +37.16% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.88 | - | 4 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.19 | - | 8 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $21 | $9.02 | +132.82% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.27 | - | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.97 | - | 1 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $350 → $300 | $126.92 | +136.37% | 6 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $112 | $195.05 | -42.58% | 10 | Jul 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $155 → $165 | $259.57 | -36.43% | 10 | May 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $12.02 | +565.56% | 9 | Sep 10, 2018 |
SOPHiA GENETICS
Apr 15, 2026
Maintains: Buy
Price Target: $7 → $8
Current: $5.00
Upside: +60.00%
Lucid Diagnostics
Mar 30, 2026
Reiterates: Buy
Price Target: $2.5
Current: $1.04
Upside: +140.38%
Ginkgo Bioworks Holdings
Mar 12, 2026
Maintains: Sell
Price Target: $9 → $5
Current: $7.85
Upside: -36.31%
Exagen
Mar 10, 2026
Maintains: Buy
Price Target: $10 → $9
Current: $2.73
Upside: +229.67%
BillionToOne
Mar 5, 2026
Maintains: Buy
Price Target: $160 → $140
Current: $78.23
Upside: +78.96%
Caris Life Sciences
Feb 27, 2026
Maintains: Buy
Price Target: $45 → $38
Current: $18.44
Upside: +106.07%
CareDx
Feb 26, 2026
Maintains: Buy
Price Target: $25 → $26
Current: $21.91
Upside: +18.67%
Tempus AI
Feb 25, 2026
Maintains: Buy
Price Target: $105 → $90
Current: $51.10
Upside: +76.13%
GeneDx Holdings
Feb 24, 2026
Maintains: Buy
Price Target: $200 → $170
Current: $66.07
Upside: +157.30%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $140 → $145
Current: $83.09
Upside: +74.51%
Feb 11, 2026
Maintains: Buy
Price Target: $12 → $13
Current: $5.50
Upside: +136.36%
Feb 6, 2026
Maintains: Buy
Price Target: $21 → $22
Current: $14.04
Upside: +56.70%
Feb 3, 2026
Maintains: Buy
Price Target: $830 → $800
Current: $568.30
Upside: +40.77%
Dec 23, 2025
Reiterates: Buy
Price Target: $7
Current: $2.04
Upside: +243.14%
Dec 12, 2025
Maintains: Buy
Price Target: $38 → $50
Current: $24.69
Upside: +102.51%
Dec 5, 2025
Maintains: Buy
Price Target: $230 → $260
Current: $200.17
Upside: +29.89%
Dec 3, 2025
Reiterates: Buy
Price Target: $160
Current: $116.65
Upside: +37.16%
Aug 11, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.88
Upside: -
Sep 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
May 2, 2024
Maintains: Buy
Price Target: $23 → $21
Current: $9.02
Upside: +132.82%
Mar 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.27
Upside: -
Jan 20, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.97
Upside: -
Sep 22, 2020
Maintains: Hold
Price Target: $350 → $300
Current: $126.92
Upside: +136.37%
Jul 24, 2019
Maintains: Buy
Price Target: $108 → $112
Current: $195.05
Upside: -42.58%
May 2, 2019
Maintains: Hold
Price Target: $155 → $165
Current: $259.57
Upside: -36.43%
Sep 10, 2018
Maintains: Buy
Price Target: $78 → $80
Current: $12.02
Upside: +565.56%